A recent study published by Rodor et al. in Cardiovascular Research identified a promising new candidate to target endothelial dysfunction in PAH—specifically, CD74, which is involved in the regulation of endothelial cell (EC) proliferation in vitro and may contribute to the progression of PAH, being considered a new candidate for future therapeutic development [95]. Here, CD74 is linked to pulmonary arterial hypertension.